BACKGROUND: Endothelins (ET-1, ET-2, ET-3) are peptides with vasoactive properties interacting with ET(A) and ET(B) receptors. ET-1 inhibits secretin-stimulated ductal secretion (hallmark of cholangiocyte growth) of cholestatic rats by interaction with ET receptors. AIM: The aims of the studies were to evaluate (i) the effect of ET-1 on cholangiocarcinoma growth in Mz-ChA-1 cells and nude mice and (ii) whether ET-1 regulation of cholangiocarcinoma growth is associated with changes in the expression of vascular endothelial growth factor-A (VEGF-A), VEGF-C, VEGF receptor-2 (VEGFR-2) and VEGFR-3. METHODS: We determined the expression of ET(A) and ET(B) receptors on normal and malignant (Mz-ChA-1) cholangiocytes and human cholangiocarcinoma tissue and the effect of ET-1 on the proliferation and expression of VEGF-A, VEGF-C (regulators of tumour angiogenesis) and its receptors, VEGFR-2 and VEGFR-3, in Mz-ChA-1 cells. In vivo, Mz-ChA-1 cells were injected into the flanks of athymic mice and injections of ET-1 or saline into the tumours were performed daily. The effect of ET-1 on tumour size, cell proliferation, apoptosis, collagen quantity and the expression of VEGF-A and VEGF-C and VEGFR-2 and VEGFR-3 were measured after 73 days. RESULTS: Higher expression of ET(A) and ET(B) was observed in malignant compared with normal cholangiocytes. ET-1 inhibited proliferation and VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression of Mz-ChA-1 cells. Chronic ET-1 treatment decreased tumour volume, tumour cell proliferation and VEGF-A and VEGF-C expression but increased apoptosis and collagen tissue deposition compared with controls. CONCLUSIONS: Modulation of VEGF-A and VEGF-C (by ET-1) may be important for managing cholangiocarcinoma growth.
BACKGROUND:Endothelins (ET-1, ET-2, ET-3) are peptides with vasoactive properties interacting with ET(A) and ET(B) receptors. ET-1 inhibits secretin-stimulated ductal secretion (hallmark of cholangiocyte growth) of cholestaticrats by interaction with ET receptors. AIM: The aims of the studies were to evaluate (i) the effect of ET-1 on cholangiocarcinoma growth in Mz-ChA-1 cells and nude mice and (ii) whether ET-1 regulation of cholangiocarcinoma growth is associated with changes in the expression of vascular endothelial growth factor-A (VEGF-A), VEGF-C, VEGF receptor-2 (VEGFR-2) and VEGFR-3. METHODS: We determined the expression of ET(A) and ET(B) receptors on normal and malignant (Mz-ChA-1) cholangiocytes and humancholangiocarcinoma tissue and the effect of ET-1 on the proliferation and expression of VEGF-A, VEGF-C (regulators of tumour angiogenesis) and its receptors, VEGFR-2 and VEGFR-3, in Mz-ChA-1 cells. In vivo, Mz-ChA-1 cells were injected into the flanks of athymic mice and injections of ET-1 or saline into the tumours were performed daily. The effect of ET-1 on tumour size, cell proliferation, apoptosis, collagen quantity and the expression of VEGF-A and VEGF-C and VEGFR-2 and VEGFR-3 were measured after 73 days. RESULTS: Higher expression of ET(A) and ET(B) was observed in malignant compared with normal cholangiocytes. ET-1 inhibited proliferation and VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression of Mz-ChA-1 cells. Chronic ET-1 treatment decreased tumour volume, tumour cell proliferation and VEGF-A and VEGF-C expression but increased apoptosis and collagen tissue deposition compared with controls. CONCLUSIONS: Modulation of VEGF-A and VEGF-C (by ET-1) may be important for managing cholangiocarcinoma growth.
Authors: Bao Luo; Liping Tang; Zhishan Wang; Junlan Zhang; Yiqun Ling; Wenguang Feng; Ju-Zhong Sun; Cecil R Stockard; Andra R Frost; Yiu-Fai Chen; William E Grizzle; Michael B Fallon Journal: Gastroenterology Date: 2005-08 Impact factor: 22.682
Authors: A Knuth; H Gabbert; W Dippold; O Klein; W Sachsse; D Bitter-Suermann; W Prellwitz; K H Meyer zum Büschenfelde Journal: J Hepatol Date: 1985 Impact factor: 25.083
Authors: Gianfranco Alpini; Pietro Invernizzi; Eugenio Gaudio; Julie Venter; Shelley Kopriva; Francesca Bernuzzi; Paolo Onori; Antonio Franchitto; Monique Coufal; Gabriel Frampton; Domenico Alvaro; Sum P Lee; Marco Marzioni; Antonio Benedetti; Sharon DeMorrow Journal: Cancer Res Date: 2008-11-15 Impact factor: 12.701
Authors: Anand Veeravagu; Andrew R Hsu; Weibo Cai; Lewis C Hou; Victor C K Tse; Xiaoyuan Chen Journal: Recent Pat Anticancer Drug Discov Date: 2007-01 Impact factor: 4.169
Authors: Alberto A Chiappori; Eric Haura; Francisco A Rodriguez; David Boulware; Rachna Kapoor; Anthony M Neuger; Richard Lush; Barbara Padilla; Michelle Burton; Charles Williams; George Simon; Scott Antonia; Daniel M Sullivan; Gerold Bepler Journal: Clin Cancer Res Date: 2008-03-01 Impact factor: 12.531
Authors: Paolo Onori; Eugenio Gaudio; Antonio Franchitto; Gianfranco Alpini; Heather Francis Journal: World J Gastrointest Pathophysiol Date: 2010-06-15
Authors: Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro Journal: Nat Rev Gastroenterol Hepatol Date: 2016-04-20 Impact factor: 46.802